Google Alert - pharmaceutical news

News 10 new results for pharmaceutical news

Bristol-Myers to buy Amylin for about $5.3 bln Moneycontrol.com Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about USD 5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon. Bristol-Myers said ... See all stories on this topic » Moneycontrol.com

Bristol-Myers to buy Amylin Pharmaceuticals gulfnews.com New York: Bristol-Myers Squibb Co agreed to pay $5.3 billion (Dh19.46 billion) to acquire Amylin Pharmaceuticals Inc, a maker of diabetes therapies, as it seeks to replace revenue from its top-selling blood thinner that's facing generic competition. See all stories on this topic »

AstraZeneca hungry to refill medicine cabinet Reuters India Faced with one of the steepest "patent cliffs" in the pharmaceutical industry, which will savage sales of its current top-selling medicines over the next five years, AstraZeneca has been under mounting pressure to do something to shore up its business ... See all stories on this topic »

Domestic pharmaceutical firm plans NT$1.1 billion investment Focus Taiwan News Channel Taipei, June 30 (CNA) ScinoPharm Taiwan Ltd., one of the leading biotechnology companies in the country, said Friday it plans to invest NT$1.1 billion (US$37.6 million) in a project to manufacture high-potency injectable drugs for cancer treatment. See all stories on this topic »

Pfizer takes Alembic to US court on drug patent Business Standard Vadodara-based Alembic and US-based Breckenridge Pharmaceutical have been named co-defendants in a suit filed by Pfizer in response to their separate Abbreviated New Drug Application (ANDA) to market desvenlafaxine succinate extended-release ... See all stories on this topic »

Bristol-Myers Squibb to buy Amylin for $7 bln AFP NEW YORK — Pharmaceutical giant Bristol-Myers Squibb announced it will purchase diabetes drug maker Amylin Pharmaceuticals, Inc. for about $7 billion. Under the deal, unanimously approved by the boards of directors of both companies, Bristol-Myers ... See all stories on this topic » AFP

Sucampo Pharmaceuticals Provides Update on Anticipated Arbitration Decision MarketWatch (press release) Sucampo Pharmaceuticals, Inc., an international pharmaceutical company is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human ... See all stories on this topic »

Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through ... MarketWatch (press release) Bristol-Myers Squibb Company (NYSE:BMY) and Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an ... See all stories on this topic »

CORRECTING and REPLACING Sucampo Pharmaceuticals Provides Update ... MarketWatch (press release) Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that the International Court of Arbitration, International Chamber of Commerce (ICC) has notified the Company of a change in the anticipated date of the decision related to the Company's ... See all stories on this topic »

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year ... MarketWatch (press release) NORTHVALE, N.J., Jun 29, 2012 (GlobeNewswire via COMTEX) -- Elite Pharmaceuticals, Inc. (OBB:ELTP) , a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations and the manufacturing ... See all stories on this topic »

---

Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »

Google Alert - pharmaceutical news

News 9 new results for pharmaceutical news

Ohr Pharmaceutical Announces $2.9 Million Financing MarketWatch (press release) Dr. Irach B. Taraporewala, CEO of Ohr Pharmaceutical, added, "This financing will allow us to comfortably achieve several upcoming milestones in our Squalamine eye drop and OHR/AVR118 clinical programs in the remainder of 2012 and 2013. We would ... See all stories on this topic »

Alembic Pharma named among co-defendants in Pfizer lawsuit Moneycontrol.com Alembic Pharmaceuticals and US-based Breckenridge Pharmaceutical have been named co-defendants in a Para IV lawsuit filed by Pfizer in relation to their abbreviated new drug application (ANDA) to market desvenlafaxine succinate extended-release ... See all stories on this topic » Moneycontrol.com

Pfizer complains against Zydus on US patent violation Business Standard For the second time in a month, a complaint of infringement of patent has been filed against Zydus Pharmaceuticals (USA), a wholly-owned subsidiary of Ahmedabad-based pharma major Cadila Health-care (Zydus Cadila) at a US district court. See all stories on this topic »

Belviq by Arena Pharmaceuticals gets approved by FDA allvoices After a long time - more than 10 years -, the Food and Drug Administration in the United States has approved a drug for weight loss for the public. See all stories on this topic »

The "race" to the weight loss pill finish line: Arena's Belviq becomes the ... The Virginian-Pilot Pharmaceutical companies are businesses focused on one primary goal; to make a lot money for their investors. Arena's latest diet pill "Belviq" is about to do just that: Make lots of money. Belviq is the first diet pill. See all stories on this topic » The Virginian-Pilot

Watson Pharmaceuticals Incorporated Stock Rating Reaffirmed by Needham ... Daily Political Watson Pharmaceuticals Incorporated (NYSE: WPI)'s stock had its hold rating restated by analysts at Needham & Company in a research report issued to. See all stories on this topic »

HC dismisses Sun Pharma's appeal on Acucal trademark Economic Times The decision came after due diligence by the court on various scientific aspects related to the suit apart from traditional crosschecks like trademark infringement, phonetic and visual similarities. See all stories on this topic »

Pharmaceutical giant goes deskless GigaOM New ways of working demand new workspaces, a fact that pharmaceutical giant GlaxoSmithKline clearly understands. It's building its second deskless office in Philadelphia, replacing cubes with fluid spaces, laptops and personal lockers, and saving money ... See all stories on this topic » GigaOM

Karen M. Jones: Pharmaceuticals aren't paying off physicians Delmarva Daily Times RE: 'Doctors ring in big bucks from drug companies,' June 10. See all stories on this topic »

---

Tip: Use a minus sign (-) in front of terms in your query that you want to exclude. Learn more.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »

Google Alert - pharmaceutical news

News 9 new results for pharmaceutical news

Arena's Diet Pill May Spur Renewed Race From Drugmakers Businessweek Arena Pharmaceuticals Inc. (ARNA)'s weight- loss pill, the first cleared in the U.S. in 13 years, and an expected rival are potential breakthroughs in the treatment of obesity that may spur major drugmakers into the market. See all stories on this topic »

US regulator clears first new weight-loss pill in 13 years NDTV The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade. Despite only achieving modest weight loss in clinical ... See all stories on this topic »

US agency approves first obesity drug in 13 years Zee News The pill called Belviq, manufactured by Arena Pharmaceutical, can be used by obese or overweight adults with at least one condition. The drug achieved only modest results in clinical studies, helping people lose on average about 5 percent of their body ... See all stories on this topic » Zee News

US FDA approves first obesity drug in 13 years Hindu Business Line The FDA said it would require Arena Pharmaceuticals - which has offices in San Diego, California and Zofingen, Switzerland - to conduct six future post-marketing studies to assess risks such as heart attack and stroke. The label will also recommend ... See all stories on this topic »

2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia ... MarketWatch (press release) Pharmaceutical companies are facing unprecedented pressures including revenue loss due to the patent cliff and growing healthcare cost containment measures introduced in most developed markets. As a result, they have been forced to reassess their ... See all stories on this topic »

TEXT-Fitch rates Watson Pharmaceuticals Reuters June 27 - Fitch Ratings has assigned a 'BBB' rating to WatsonPharmaceuticals, Inc.'s (Watson) (NYSE: WPI) new five-year seniorunsecured term loan facility with an aggregate principal amount of $1.8 billion.Watson's. See all stories on this topic »

FDA OKs first obesity drug in 13 years Chicago Tribune NEW YORK/WASHINGTON (Reuters) - U.S. health regulators approved the first new weight-loss drug in 13 years, allowing Arena Pharmaceuticals Inc to bring its Belviq pill to market as public health advocates push for new solutions to the nation's growing ... See all stories on this topic »

Arena Pharmaceuticals and Eisai Announce FDA Approval of BELVIQ ... Sacramento Bee PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical ... See all stories on this topic »

Obesity pill Belviq: FDA approves first long-term prescription weight loss ... Daily Mail Arena Pharmaceutical's anti-obesity pill Belviq, despite only achieving modest weight loss in clinical studies, appears safe enough to win the FDA's endorsement amid calls from doctors for new weight-loss treatments. The agency cleared the pill ... See all stories on this topic » Daily Mail

---

This once a day Google Alert is brought to you by Google.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »

Google Alert - pharmaceutical news

News 9 new results for pharmaceutical news

Pharma bigwigs including Abbott, Bayer, GlaxoSmithKline, Sanofi ... Economic Times Seven pharmaceutical companies and four research institutions have teamed up with the Bill and Melinda Gates Foundation for the goal. See all stories on this topic »

Tonix Pharmaceuticals to Present at LHA Life Sciences & Medical ... MarketWatch (press release) NEW YORK, Jun 27, 2012 (BUSINESS WIRE) -- Tonix Pharmaceuticals Holding Corp. (OBB:TNXP) ("TONIX" or the "Company"), which specializes in ... See all stories on this topic »

Kedem Pharmaceuticals to Appoint New Chief Operating Officer MarketWatch (press release) Dr. Maksumova joined Kedem Pharmaceuticals in 2011. She has brought over two decades of highly professional experience in drug research and product ... See all stories on this topic »

China Pharmaceutical says to buy $1.16 bln assets from parent Reuters HONG KONG, June 27 (Reuters) - China Pharmacuetical GroupLtd said it would buy pharmaceutical assets from itsparent company for HK$8.98 billion ($1.16 ... See all stories on this topic »

Biggest Names in Pharmaceutical, Healthcare Industry to Gather for ... MarketWatch (press release) "Under the guidance of conference co-chairs representing high-level leadership at Merck and Pfizer, this event offers the very best in pharmaceutical competitive ... See all stories on this topic »

Prodigy Health Supplier Partners with Stason Pharmaceuticals to ... Sacramento Bee PRNewswire/ -- Prodigy Health Supplier entered a Joint Venture with Stason Pharmaceuticals to bring a diverse line of quality generic pharmaceuticals to the ... See all stories on this topic »

The Implied Move: Arena Pharmaceutical Optionetics Arena Pharmaceutical (ARNA) is a small capper, clinical stage biopharmaceutical facing a decision by the FDA today (PDUFA date) regarding its weight loss ... See all stories on this topic »

Elite Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal ... MarketWatch (press release) NORTHVALE, N.J., Jun 27, 2012 (GlobeNewswire via COMTEX) -- Elite Pharmaceuticals, Inc. (OBB:ELTP) , a specialty pharmaceutical company dedicated to ... See all stories on this topic »

NPS Pharmaceuticals Launches Educational Website on ... EON: Enhanced Online News (press release) NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine. See all stories on this topic » EON: Enhanced Online News (press release)

---

This once a day Google Alert is brought to you by Google.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »

Google Alert - pharmaceutical news

News 8 new results for pharmaceutical news

Thomson Reuters Annual Pharmaceutical Factbook Reveals Key ... Reuters Fewer projects with higher success rates show focus on quality paying off London, UK, 26 June 2012 - The In. See all stories on this topic »

NPS Pharmaceuticals Launches Educational Website on ... MarketWatch (press release) NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. See all stories on this topic »

European Pharmaceutical Leader Gedeon Richter Selects Psion ... MarketWatch (press release) "The business features of this rugged device make it the ideal tool for the pharmaceutical industry, offering workers access to robust and accurate information, ... See all stories on this topic »

Hot Stocks: Arena Pharmaceuticals, Teva, Cemex, Occidental ... MarketWatch (press release) Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) : In the last trading session, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) slipped 6.93% to US$9.19, which was ... See all stories on this topic »

Pharmaceutical exports estimated to reach $82b China Daily By 2015, the annual exports of the pharmaceutical industry will reach $82 billion, with an annual growth rate of over 20 percent, reported Shanghai Securities ... See all stories on this topic »

The Zacks Analyst Blog Highlights: Teva Pharmaceutical, Momenta ... Sacramento Bee PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and ... See all stories on this topic »

Presidio Pharmaceuticals Successfully Completes Phase 1 Proof-of ... MarketWatch (press release) Presidio Pharmaceuticals Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients with Genotype-1 ... See all stories on this topic »

Natco loses US patent suit by Israeli pharma major Teva Economic Times India's Natco Pharma has lost a patent infringement suit in the US filed by Israeli pharma major Teva over sale of Copaxone, a drug used to treat multiple ... See all stories on this topic »

---

Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »

Google Alert - pharmaceutical news

News 9 new results for pharmaceutical news

Natco Pharma loses patent case against Teva Pharmaceutical ... Economic Times Natco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug, Copaxone. See all stories on this topic »

Natco, Mylan to appeal against New York district court verdict Economic Times The decision by the US court covers several patents for the chemical composition of Copaxone, methods of using the product and processes for manufacturing ... See all stories on this topic »

Synergy Pharmaceuticals Added to the Russell 3000(R), Russell ... MarketWatch (press release) NEW YORK, Jun 25, 2012 (GlobeNewswire via COMTEX) -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) (NASDAQ:SGYPU) (NASDAQ:SGYPW) , a ... See all stories on this topic »

Natco Pharma tanks after losing patent case against Teva Hindu Business Line Natco Pharma Ltd faced a setback in the patent infringement case with Teva Pharmaceuticals pertaining to the generic version of Copaxone. Copaxone is ... See all stories on this topic »

Momenta shares drop as co loses patent lawsuit Reuters (Reuters) - Shares of Momenta Pharmaceuticals Inc (MNTA.O) slipped 22 percent on Monday after the company lost a patent lawsuit brought against it by bigger ... See all stories on this topic »

Federal court backs Teva Pharmaceutical patents behind multiple ... Washington Post Shares of Teva Pharmaceutical Industries Ltd. are soaring in the first trading day after a federal court backed patents protecting the drugmaker's biggest ... See all stories on this topic »

Pharmaceuticals Swing; Teva, Pfizer, Bristol-Myers Moving Early Barron's (blog) Pharmaceutical stocks are moving early on Monday as investors react to news out of the FDA and the courts. Teva Pharmaceuticals (TEVA) rose 6.4% after a ... See all stories on this topic »

Ahead of the Bell: Court backs Teva patents Businessweek Shares of Teva Pharmaceutical Industries Ltd. climbed in premarket trading Monday after the drugmaker said a federal court reaffirmed patents protecting its ... See all stories on this topic »

Teva wins Copaxone patent infringement lawsuit in US against ... pharmabiz.com Teva Pharmaceutical Industries has won Copaxone patent infringement litigation lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan ... See all stories on this topic »

---

Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »

Google Alert - pharmaceutical news

News 10 new results for pharmaceutical news

Teva shares jump on positive Copaxone patent ruling Moneycontrol.com JERUSALEM (Reuters) - Teva Pharmaceutical Industries rose more than 11 percent on Sunday after a U.S. court upheld Teva's patents for multiple sclerosis ... See all stories on this topic » Moneycontrol.com

Teva shares jump on positive Copaxone patent ruling IBNLive.com By Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries rose more than 11 percent on Sunday after a U.S. court upheld Tevas patents for ... See all stories on this topic »

Shengtai Pharmaceutical, Inc. Special Committee Selects Financial ... Business Review India (press release) WEIFANG, Shandong, China, June 23, 2012 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the ... See all stories on this topic »

Pharma cos stay mum as govt seeks details of overcharging Hindustan Times Even after four months of receiving overcharging notices from the department of pharmaceuticals (DoP), not even one of the 500-odd pharma companies have ... See all stories on this topic »

OPINION: Pharmaceutical reps overtime ruling protects FLSA ... Business Insurance The U.S. Supreme Court prevented a potential flood of litigation with last week's ruling in a case involving eligibility for overtime pay. As we report on page 3, ... See all stories on this topic »

Teva Jumps Most Since 2000 on Copaxone Ruling in US Businessweek Teva Pharmaceutical Industries Ltd. (TEVA) jumped the most in more than 12 years after a U.S. federal district judge ruling may block generic versions of its ... See all stories on this topic »

Leader upgrades Teva Globes Leader Capital Markets today raised its recommendation for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) to "Buy" from "Outperform", with a ... See all stories on this topic »

Teva soars on Copaxone patents victory Globes Shares in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) are up 7.95% at NIS 157.50 on the Tel Aviv Stock Exchange, following a victory by ... See all stories on this topic »

You Can't Have Free Trade and Price Controls: Pharmaceutical ... Forbes This is a nice example of the fact that in economics there are no such things as solutions. There are only possible trade offs. In this case the trade off is between ... See all stories on this topic »

Teva's problems are delayed, not solved Globes 24 June 12 18:38, Gali Weinreb. The legal decision does not solve any of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA; TASE: TEVA) strategic problems. See all stories on this topic »

---

Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.

Delete this alert.
Create another alert.
Manage your alerts.

Read more »